Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pioglitazone-containing pharmaceutical composition in diabetes prevention

A technology for pioglitazone and a composition is applied in the field of pharmaceutical compositions containing pioglitazone, which can solve the problems of increasing collagen non-genomic effect, tissue damage of insulin sensitivity, insulin resistance, etc. Correcting the effect of IR

Inactive Publication Date: 2017-03-22
刘英
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(5) Non-genomic effects of increased collagen synthesis or fibrosis leading to insulin production or damage to insulin-sensitive tissues
(6) Hypokalemia can significantly reduce the function of insulin to promote glucose uptake in cells, thus causing insulin resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pioglitazone-containing pharmaceutical composition in diabetes prevention
  • Application of pioglitazone-containing pharmaceutical composition in diabetes prevention
  • Application of pioglitazone-containing pharmaceutical composition in diabetes prevention

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015] The present invention will be further described in detail below in conjunction with specific embodiments.

[0016] 130 patients with IGT (impaired glucose tolerance) were observed, among them, FBG5.5~7.0mmol / L, 2hBG 7.8~11.1mmol / L, in line with the 1999 WHO and 2003 American Diabetes Association (ADA) diagnostic criteria. Patients underwent oral 75g glucose tolerance test.

[0017] Cases with the following exceptions:

[0018] (1) A clear diagnosis of diabetes in the past;

[0019] (2) There has been a history of hormone drug use within half a year;

[0020] (3) Abnormal liver and kidney function tests;

[0021] (4) Excessive acute and chronic pancreatitis in the past;

[0022] (5) Family history of bladder cancer;

[0023] (6) Cardiac insufficiency (NYHA classification: Ⅲ~Ⅳ);

[0024] (7) Electrolyte disturbance;

[0025] (8) hypotension;

[0026] (9) Other serious diseases;

[0027] (10) Physicians think that it is not suitable for candidates.

[0028] Divid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a pioglitazone-containing pharmaceutical composition in diabetes prevention. The harmaceutical composition comprises the following active components: pioglitazone or derivative thereof and spirolactone or derivative thereof, wherein the weight ratio of the pioglitazone to spirolactone is 1:(0.8-3). In the invention, the edema and weight gain of an IGT patient in a treatment process adopting pioglitazone are avoided better, more stable postprandial blood sugar can be realized, and the IR of the IGT patient can be effectively corrected to prevent or delay the attack and development of diabetes and complications thereof.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of a pharmaceutical composition containing pioglitazone in preventing diabetes. Background technique [0002] The prevalence of diabetes in my country rose from 4.5% in 2002 to 9.7% in 2007, and there is still a rising trend. IGT (Impaired Glucose Tolerance) patients are generally believed to be pre-diabetic populations. It has been reported at home and abroad that 5% to 10% of IGT patients will develop into diabetes each year. A number of studies have shown that in addition to abnormal glucose metabolism, IGT may also cause multiple metabolic injuries such as hyperlipidemia, hypertension, and obesity, and interact with each other, leading to the occurrence and development of complications such as multi-system blood vessels and nerves. At present, a large amount of evidence-based medical evidence shows that the main pathophysiological basis for the development of type 2 d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/585A61K31/4439A61P3/10
CPCA61K31/585A61K31/4439A61K2300/00
Inventor 刘英何磊何屹添何弈嘉
Owner 刘英
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com